A Phase I Trial of Peptide-Based Glioma Vaccine IMA950 in Patients With Glioblastoma (GBM).

Trial Profile

A Phase I Trial of Peptide-Based Glioma Vaccine IMA950 in Patients With Glioblastoma (GBM).

Discontinued
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2014

At a glance

  • Drugs IMA 950 (Primary) ; Cyclophosphamide; Granulocyte macrophage colony stimulating factor; Imiquimod; Subunit vaccines
  • Indications Glioblastoma
  • Focus Adverse reactions; Biomarker; Pharmacodynamics
  • Sponsors immatics biotechnologies GmbH
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 May 2014 Status changed from active, no longer recruiting to discontinued, as per ClinicalTrials.gov record.
    • 14 May 2014 Status changed from active, no longer recruiting to discontinued, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top